ClinicalTrials.gov
public full text
Public Domain
Efficacy and Safety of Dacomitinib in the Treatment of Skin Squamous Cell Cancer
This is an open label, monocentric, uncontrolled phase II trial with Dacomitinib, a pan-HER inhibitor, in unresectable or metastatic skin SCC. HER2 expression is common in skin SCC, being reported with high rates, even if in small studies. Coexpression of EGFR, HER2 and HER3 is present in skin SCCs but not in normal skin and it could be associated with the malignant phenotype. In this frame Dacomitinib could play a role in the increase of the response rate.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- GW572016 In Patients With ErbB2 Over - Expressing Advanced Or Metastatic Breast Cancer#855772
- Erlotinib in Women With Squamous Cell Carcinoma of the Vulvar#1420912
- D2C7-IT With Atezolizumab for Recurrent Gliomas#848505
- Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2#6895
- Safety and Efficacy Real-world Data of Trastuzumab Deruxtecan and Sacituzumab Govitecan#1009170
Record · ID 1487065
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive